BackAcadia Pharmaceuticals Overview
Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Target Price

Where could ACAD trade next? Consensus target price: $32.

Get informed when a big investor buys or sells

+ Follow

Share Price

$29.45

Average Target Price

$31.647.4% upside

7 analysts in the last 4 months

High: $37 | Low: $14.5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-05RBC CapitalBrian Abrahams$3725.6% upsideOpen
2026-08-05OppenheimerMatthew Hershenhorn$2515.1% downsideOpen
2026-07-29Raymond James$14.550.8% downsideOpen
2026-07-21BMO Capital$3622.2% upsideOpen
2026-07-07RBC CapitalBrian Abrahams$3622.2% upsideOpen
2026-06-29Deutsche BankDavid Hoang$3725.6% upsideOpen
2026-06-29Canaccord GenuitySumant Kulkarni$3622.2% upsideOpen
2026-03-02William Blair$291.5% downsideOpen
2026-02-23Wolfe ResearchRudy Li$3312.1% upsideOpen
2026-02-23Mizuho Securities$3518.8% upsideOpen
2026-02-03RBC Capital$315.3% upsideOpen
2026-01-06UBSAshwani Verma$4035.8% upsideOpen
2026-01-05Needham$3415.4% upsideOpen
2025-12-16Stifel Nicolaus$3725.6% upsideOpen
2025-12-16Piper Sandler$3725.6% upsideOpen
2025-12-15H.C. Wainwright$3725.6% upsideOpen
2025-12-11Stifel NicolausPaul Matteis$2515.1% downsideOpen
2025-12-04UBSAshwani Verma$3518.8% upsideOpen
2025-12-02Mizuho Securities$291.5% downsideOpen
2025-09-25Deutsche Bank$291.5% downsideOpen
2025-09-09UBS$3932.4% upsideOpen
2025-08-08UBSAshwani Verma$3622.2% upsideOpen
2025-06-26OppenheimerMatthew Hershenhorn$2225.3% downsideOpen
2025-05-20Morgan StanleySean Laaman$2418.5% downsideOpen
2025-05-19NeedhamAmi Fadia$301.9% upsideOpen
2025-05-19H.C. WainwrightAndrew Fein$328.7% upsideOpen
2025-04-28UBS$2225.3% downsideOpen
2025-01-03GuggenheimYatin Suneja$2032.1% downsideOpen
2024-08-07Morgan StanleyJeffrey Hung$2032.1% downsideOpen
2024-06-26BMO CapitalKeith Tapper$315.3% upsideOpen
2024-05-09H.C. WainwrightAndrew Fein$278.3% downsideOpen
2024-05-09Robert W. BairdJoel Beatty$284.9% downsideOpen
2024-05-09Mizuho SecuritiesUy Ear$2128.7% downsideOpen
2024-04-30UBSAshwani Verma$278.3% downsideOpen
2024-03-12UBSAshwani Verma$3312.1% upsideOpen
2024-03-12OppenheimerJay Olson$1935.5% downsideOpen
2024-03-12NeedhamAmi Fadia$328.7% upsideOpen
2024-03-12Canaccord GenuitySumant Kulkami$3312.1% upsideOpen
2024-03-12JMP SecuritiesJason Butler$3932.4% upsideOpen
2024-01-24NeedhamAmi Fadia$3725.6% upsideOpen
2022-11-14J.P. Morgan$1742.3% downsideOpen
2022-08-09Morgan Stanley$1838.9% downsideOpen
2022-08-09Mizuho Securities$1935.5% downsideOpen
2022-08-09Goldman Sachs$1549.1% downsideOpen
2022-08-09RBC Capital$2128.7% downsideOpen
2022-08-09H.C. Wainwright$2515.1% downsideOpen
2022-08-09Leerink Partners$2128.7% downsideOpen
2022-08-08Cowen & Co.$2128.7% downsideOpen
2022-07-15Morgan Stanley$2225.3% downsideOpen
2022-07-11Leerink Partners$278.3% downsideOpen

Acadia Pharmaceuticals (ACAD) FAQ

The latest target price for ACAD is $32. Investors often review this figure alongside Acadia Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Acadia Pharmaceuticals trades near $29.45 while the consensus target sits at $32 (7.4% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting ACAD's target price ($32), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Acadia Pharmaceuticals's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.